In this episode of The Crux of Cardio, Jordan is joined by Dr. Michael Reardon, Professor and Chief of Cardiac Surgery at Houston Methodist Hospital, to explore the evolution of transcatheter aortic valve replacement (TAVR), the lessons learned from more than 3,000 procedures, and the critical questions that remain unanswered in structural heart disease. With more than four decades of experience in cardiac surgery, Dr. Reardon shares how a once-radical idea has transformed the treatment of aortic stenosis, allowing many patients to return home the day after treatment. From the importance of patient selection and long-term valve durability to the future of transcatheter technology, he explains why the biggest decisions often happen long before a patient enters the cath lab. The conversation also explores the realities of designing and running pivotal clinical trials, the role of the multidisciplinary heart team, and how emerging technologies such as the Dura-AVR valve could reshape the future of aortic valve replacement.